The CDC studied 692,570 adult COVID-19 outpatients around the country in the weeks of April-July 2022, and found that Black patients in each age group were less likely to receive Paxlovid, the leading antiviral treatment available. These are the percentages of patients of each racial and age group who received the treatment.